189 related articles for article (PubMed ID: 19717419)
1. Expression of neuropeptide hormone receptors in human adrenal tumors and cell lines: antiproliferative effects of peptide analogues.
Ziegler CG; Brown JW; Schally AV; Erler A; Gebauer L; Treszl A; Young L; Fishman LM; Engel JB; Willenberg HS; Petersenn S; Eisenhofer G; Ehrhart-Bornstein M; Bornstein SR
Proc Natl Acad Sci U S A; 2009 Sep; 106(37):15879-84. PubMed ID: 19717419
[TBL] [Abstract][Full Text] [Related]
2. Anti-tumor effects of peptide analogs targeting neuropeptide hormone receptors on mouse pheochromocytoma cells.
Ziegler CG; Ullrich M; Schally AV; Bergmann R; Pietzsch J; Gebauer L; Gondek K; Qin N; Pacak K; Ehrhart-Bornstein M; Eisenhofer G; Bornstein SR
Mol Cell Endocrinol; 2013 May; 371(1-2):189-94. PubMed ID: 23267837
[TBL] [Abstract][Full Text] [Related]
3. Therapy of experimental hepatic cancers with cytotoxic peptide analogs targeted to receptors for luteinizing hormone-releasing hormone, somatostatin or bombesin.
Szepeshazi K; Schally AV; Treszl A; Seitz S; Halmos G
Anticancer Drugs; 2008 Apr; 19(4):349-58. PubMed ID: 18454045
[TBL] [Abstract][Full Text] [Related]
4. Receptors for luteinizing hormone releasing hormone expressed on human renal cell carcinomas can be used for targeted chemotherapy with cytotoxic luteinizing hormone releasing hormone analogues.
Keller G; Schally AV; Gaiser T; Nagy A; Baker B; Halmos G; Engel JB
Clin Cancer Res; 2005 Aug; 11(15):5549-57. PubMed ID: 16061872
[TBL] [Abstract][Full Text] [Related]
5. The inhibitory effect of a novel cytotoxic somatostatin analogue AN-162 on experimental glioblastoma.
Pozsgai E; Schally AV; Halmos G; Rick F; Bellyei S
Horm Metab Res; 2010 Oct; 42(11):781-6. PubMed ID: 20665426
[TBL] [Abstract][Full Text] [Related]
6. Somatostatin receptor expression in adrenocortical tumors and effect of a new somatostatin analog SOM230 on hormone secretion in vitro and in ex vivo adrenal cells.
Mariniello B; Finco I; Sartorato P; Patalano A; Iacobone M; Guzzardo V; Fassina A; Mantero F
J Endocrinol Invest; 2011 Jun; 34(6):e131-8. PubMed ID: 21042045
[TBL] [Abstract][Full Text] [Related]
7. Cellular mechanisms of growth inhibition of human endometrial cancer cell line by an antagonist of growth hormone-releasing hormone.
Zhao L; Yano T; Osuga Y; Nakagawa S; Oishi H; Wada-Hiraike O; Tang X; Yano N; Kugu K; Schally AV; Taketani Y
Int J Oncol; 2008 Mar; 32(3):593-601. PubMed ID: 18292936
[TBL] [Abstract][Full Text] [Related]
8. Expression of growth hormone-releasing hormone receptor splicing variants in human primary adrenocortical tumours.
Freddi S; Arnaldi G; Fazioli F; Scarpelli M; Appolloni G; Mancini T; Kola B; Bertagna X; Mantero F; Collu R; Boscaro M
Clin Endocrinol (Oxf); 2005 May; 62(5):533-8. PubMed ID: 15853821
[TBL] [Abstract][Full Text] [Related]
9. Triple-negative breast cancers express receptors for luteinizing hormone-releasing hormone (LHRH) and respond to LHRH antagonist cetrorelix with growth inhibition.
Buchholz S; Seitz S; Schally AV; Engel JB; Rick FG; Szalontay L; Hohla F; Krishan A; Papadia A; Gaiser T; Brockhoff G; Ortmann O; Diedrich K; Köster F
Int J Oncol; 2009 Oct; 35(4):789-96. PubMed ID: 19724914
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of proliferation of small intestinal and bronchopulmonary neuroendocrine cell lines by using peptide analogs targeting receptors.
Kidd M; Schally AV; Pfragner R; Malfertheiner MV; Modlin IM
Cancer; 2008 Mar; 112(6):1404-14. PubMed ID: 18224665
[TBL] [Abstract][Full Text] [Related]
11. Expression of receptors for luteinizing hormone-releasing hormone in human ovarian and endometrial cancers: frequency, autoregulation, and correlation with direct antiproliferative activity of luteinizing hormone-releasing hormone analogues.
Völker P; Gründker C; Schmidt O; Schulz KD; Emons G
Am J Obstet Gynecol; 2002 Feb; 186(2):171-9. PubMed ID: 11854630
[TBL] [Abstract][Full Text] [Related]
12. The effects of GH-releasing hormone/somatostatin on the 5'-promoter activity of the GH gene in vitro.
Morishita M; Iwasaki Y; Onishi A; Asai M; Mutsuga N; Yoshida M; Oiso Y; Inoue K; Murohara T
J Mol Endocrinol; 2003 Dec; 31(3):441-8. PubMed ID: 14664705
[TBL] [Abstract][Full Text] [Related]
13. Expression of mRNA for growth hormone-releasing hormone and splice variants of GHRH receptors in human malignant bone tumors.
Busto R; Schally AV; Braczkowski R; Plonowski A; Krupa M; Groot K; Armatis P; Varga JL
Regul Pept; 2002 Oct; 108(2-3):47-53. PubMed ID: 12220726
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of human non-small cell lung cancers with a targeted cytotoxic somatostatin analog, AN-162.
Treszl A; Schally AV; Seitz S; Szalontay L; Rick FG; Szepeshazi K; Halmos G
Peptides; 2009 Sep; 30(9):1643-50. PubMed ID: 19524629
[TBL] [Abstract][Full Text] [Related]
15. Effect of GHRH and GHRP-2 treatment in vitro on GH secretion and levels of GH, pituitary transcription factor-1, GHRH-receptor, GH-secretagogue-receptor and somatostatin receptor mRNAs in ovine pituitary cells.
Yan M; Hernandez M; Xu R; Chen C
Eur J Endocrinol; 2004 Feb; 150(2):235-42. PubMed ID: 14763922
[TBL] [Abstract][Full Text] [Related]
16. Effective treatment of experimental human endometrial cancers with targeted cytotoxic luteinizing hormone-releasing hormone analogues AN-152 and AN-207.
Engel JB; Keller G; Schally AV; Nagy A; Chism DD; Halmos G
Fertil Steril; 2005 Apr; 83 Suppl 1():1125-33. PubMed ID: 15831285
[TBL] [Abstract][Full Text] [Related]
17. Antiproliferative effect of growth hormone-releasing hormone (GHRH) antagonist on ovarian cancer cells through the EGFR-Akt pathway.
Guo J; Schally AV; Zarandi M; Varga J; Leung PC
Reprod Biol Endocrinol; 2010 May; 8():54. PubMed ID: 20509930
[TBL] [Abstract][Full Text] [Related]
18. Differential expression of the human somatostatin receptor subtypes sst1 to sst5 in various adrenal tumors and normal adrenal gland.
Ueberberg B; Tourne H; Redmann A; Walz MK; Schmid KW; Mann K; Petersenn S
Horm Metab Res; 2005 Dec; 37(12):722-8. PubMed ID: 16372224
[TBL] [Abstract][Full Text] [Related]
19. Growth hormone (GH)-releasing hormone (GHRH) and the GH secretagogue (GHS), L692,585, differentially modulate rat pituitary GHS receptor and GHRH receptor messenger ribonucleic acid levels.
Kineman RD; Kamegai J; Frohman LA
Endocrinology; 1999 Aug; 140(8):3581-6. PubMed ID: 10433214
[TBL] [Abstract][Full Text] [Related]
20. Dose-dependent growth inhibition in vivo of PC-3 prostate cancer with a reduction in tumoral growth factors after therapy with GHRH antagonist MZ-J-7-138.
Heinrich E; Schally AV; Buchholz S; Rick FG; Halmos G; Mile M; Groot K; Hohla F; Zarandi M; Varga JL
Prostate; 2008 Dec; 68(16):1763-72. PubMed ID: 18729085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
